Back to Search
Start Over
Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use
- Source :
- Expert Review of Endocrinology & Metabolism. 5:799-807
- Publication Year :
- 2010
- Publisher :
- Informa UK Limited, 2010.
-
Abstract
- Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve β-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. Sin financiación 0.213 SJR (2010) Q3, 114/183 Endocrinology, diabetes and metabolism UEM
- Subjects :
- medicine.medical_specialty
endocrine system diseases
business.industry
Liraglutide
Endocrinology, Diabetes and Metabolism
Diabetes
Enfermedad cardiovascular
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
Incretin
Type 2 diabetes
Pharmacology
Hypoglycemia
medicine.disease
Diabetes tipo 2
Metformin
Clinical trial
Internal medicine
Diabetes mellitus
medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 17448417 and 17446651
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Expert Review of Endocrinology & Metabolism
- Accession number :
- edsair.doi.dedup.....133c271a7e9f9e56e76eea79e0ece928